Heikki Kuusanmaki

Helsinki, Finland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 39 publications

Early venetoclax dose escalation at minimal residual disease progression may benefit selected acute myeloid leukaemia patients.

Early venetoclax dose escalation at minimal residual disease progression may benefit selected acute myeloid leukaemia patients.

Journal: British journal of haematology

Published: March 05, 2026

Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML.

Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML.

Journal: Cell stem cell

Published: October 09, 2025

Drivers of clinical resistance to venetoclax and hypomethylating agents in acute myeloid leukemia and strategies for improving efficacy.

Drivers of clinical resistance to venetoclax and hypomethylating agents in acute myeloid leukemia and strategies for improving efficacy.

Journal: HemaSphere

Published: June 24, 2025

Predictors of response and rational combinations for the novel MCL-1 inhibitor MIK665 in acute myeloid leukemia.

Predictors of response and rational combinations for the novel MCL-1 inhibitor MIK665 in acute myeloid leukemia.

Journal: Molecular oncology

Published: February 06, 2025

Capillary Sampling Enables Venetoclax Concentration Measurement in Acute Myeloid Leukaemia Within Academic Multicentre Trial.

Capillary Sampling Enables Venetoclax Concentration Measurement in Acute Myeloid Leukaemia Within Academic Multicentre Trial.

Journal: Basic & clinical pharmacology & toxicology

Published: November 18, 2024

CLEVER-1 targeting antibody, bexmarilimab, supports HLA-DR expression and alters ex vivo responsiveness to azacitidine and venetoclax in myeloid malignancies.

CLEVER-1 targeting antibody, bexmarilimab, supports HLA-DR expression and alters ex vivo responsiveness to azacitidine and venetoclax in myeloid malignancies.

Journal: Scientific reports

Published: November 16, 2024

A Machine Learning-Based Strategy Predicts Selective and Synergistic Drug Combinations for Relapsed Acute Myeloid Leukemia.

A Machine Learning-Based Strategy Predicts Selective and Synergistic Drug Combinations for Relapsed Acute Myeloid Leukemia.

Journal: Cancer research

Published: October 15, 2024

Digital twin models for predicting venetoclax and azacitidine-induced neutropenia in patients with acute myeloid leukemia.

Digital twin models for predicting venetoclax and azacitidine-induced neutropenia in patients with acute myeloid leukemia.

Journal: NPJ digital medicine

Published: August 31, 2024

High-throughput drug screening identifies SMAC mimetics as enhancers of NK-cell cytotoxicity in chronic myeloid leukemia.

High-throughput drug screening identifies SMAC mimetics as enhancers of NK-cell cytotoxicity in chronic myeloid leukemia.

Journal: Blood

Published: May 17, 2024

Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial.

Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial.

Journal: Blood

Published: April 11, 2024

Dual specific STAT3/5 degraders effectively block acute myeloid leukemia and natural killer/T cell lymphoma.

Dual specific STAT3/5 degraders effectively block acute myeloid leukemia and natural killer/T cell lymphoma.

Journal: HemaSphere

Published: December 06, 2023

Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab-Auristatin Conjugate with a Wide Therapeutic Window.

Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab-Auristatin Conjugate with a Wide Therapeutic Window.

Journal: Molecular cancer therapeutics

Published: October 19, 2023

Showing 1-12 of 39

Last Updated: 09/26/2026